Navigation Links
Novel surgery removes rare tumor, rebuilds trachea
Date:1/28/2011

DETROIT Using a novel surgical approach, it's possible to rebuild the trachea and preserve a patient's voice after removing an invasive throat tumor, according to a new report from Henry Ford Hospital in Detroit.

This case study is the first of its kind to not only document a successful technique to create a fully functional trachea, or windpipe, but also report a rare type of malignant tumor in an adult's trachea. Most commonly, this type of tumor is seen in newborns and very rarely occurs in the neck, says lead study author Samer Al-Khudari, M.D., with the Department of Otolaryngology-Head & Neck Surgery at Henry Ford Hospital.

"In this case, the patient's tumor had spread to the trachea, thyroid gland, muscles around the thyroid gland and nerves in the area," says Dr. Al-Khudari.

According to head and neck cancer surgeon Tamer A. Ghanem, M.D., Ph.D., who led the Henry Ford surgical team, the easiest approach would have been to remove the trachea and the voice box, given the tumor's proximity to the larynx and other surrounding structures. With this method, however, the patient would no longer be able to speak or swallow normally.

Instead, the surgical team took another approach. Using tissue and bone from the patient's arm, they were able to reconstruct the trachea, restoring airflow through the trachea and saving the patient's voice.

"We had to think outside the box to not only safely remove the tumor, but to allow for optimum functional outcome," says Dr. Ghanem, director of the Head and Neck Oncology & Microvascular Surgery Division at Henry Ford. "This is the first time such a large portion of a patient's trachea has been removed and rebuilt in a way that allows it to be fully functional."

This unique case will be presented Jan. 29 at the poster session for the Triological Society's Combined Section Meeting in Scottsdale, Ariz.

The case study is centered on a 27 year-old man who had a large mass blocking 90 percent of his airway, making it very difficult for him to breathe.

After a biopsy and other tests, Henry Ford doctors determined the mass was a malignant immature teratoma a cancerous tumor that was quickly spreading throughout the areas of the patient's trachea and surrounding structures.

Such tumors are extremely rare; since the first reported case in 1854, there have only been 300 other reported cases.

With the Henry Ford patient, surgeons first removed the tumor and about half of the patient's airway, just below the voice box.

Using bone and skin from the patient's arm and two titanium plates, surgeon's reconstructed the airway, providing it with full coverage and allowing it to be fully functional.

Reconstruction of the trachea is challenging, due to the structural complexity and unique properties of the airway. The ideal reconstruction must not collapse during respiration and have some degree of mobility to allow for neck movement.

Currently the patient is using a tracheostomy tube a tube that is inserted into an opening in the trachea to assist with breathing but the surgeons do not expect it to be permanent. The patient, however, is able to speak and swallow normally. He also underwent chemotherapy as part of his treatment.


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Researchers reveal function of novel molecule that underlies human deafness
2. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
3. UCI researchers find novel memory-enhancing mechanism in brain
4. Novel imaging technique may reduce lymphedema in breast cancer patients
5. New standards of care and novel treatment options for several forms of lymphoma unveiled
6. Novel genetic mutation that causes the most common form of eye cancer discovered
7. Quebec City researchers pave the way for novel treatment of pulmonary hypertension
8. Eat safer: Novel approach detects unknown food pathogens
9. Novel Drug Eases Osteoarthritis Knee Pain
10. Novel biomarker may predict response to new VEGF receptor inhibitor
11. Novel Rheumatoid Arthritis Drug Shows Early Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... Compliancy Group LLC is pleased to offer ... the country. The Guard was specifically designed to handle each element required for ... updates, and compliance coaching. , In addition to meeting the compliance needs of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize ... can leave patients with dental emergencies at risk of losing a tooth or their ... care. , Common dental emergencies include:, , Avulsed or ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... Indianapolis, IN (PRWEB) , ... February 10, 2016 ... ... employee benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its ... and has seven other locations throughout the Southeast, from Orlando to Huntsville and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016 /PRNewswire/ ... a synergistic confluence of various technologies that ... propositions, previously unavailable. These opportunities create a ... convergence, in turn, drives the development of ... scenario is characterized by technology convergences, which ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology: